Medical experts in small cell lung cancer convene to examine first-line treatments, ongoing clinical trials, and emerging therapies shaping the evolving treatment landscape.
Video Player is loading.
Play Video
Play
Mute
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
Seek to live, currently behind liveLIVE
Remaining Time -0:00
1x
Playback Rate
2x
1.75x
1.5x
1.25x
1x, selected
0.75x
0.5x
Chapters
Chapters
Descriptions
descriptions off, selected
Captions
captions settings, opens captions settings dialog
captions off, selected
Audio Track
Fullscreen
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
Reset restore all settings to the default valuesDone
Close Modal Dialog
End of dialog window.
Close Modal Dialog
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Briefly explore the current landscape of first-line treatment for limited-stage small cell lung cancer:
What clinical factors influence or impact the initial diagnostic workup and management of patients with LS-SCLC?
To what degree is a multidisciplinary team approach adopted when developing a treatment plan for patients with SCLC?
With respect to limited-stage disease, which patients are most likely to benefit from surgery and does lobectomy remain the preferred procedure for stageI-IIA (T1-2,N0,M0) disease?
To what degree does pathologic mediastinal lymph node stage influence your treatment path?
Under what circumstances would surgery versus RT be a preferred approach for a patient with stage I-IIA SCLC?
Newsletter
Stay up to date on the most recent and practice-changing oncology data